Insights & news

Belgium - Bill Facilitating Biosimilar Market Entry in Hospital Channel

  • 02/09/2021
  • Articles

Member of Parliament Nawal Farih submitted in June 2021 a private member’s bill which seeks to facilitate market entry by biosimilar medicines (Bill 2157K001 – Wetsvoorstel tot wijziging van de Wet betreffende de verplichte verzekering voor geneeskundige verzorging en uitkeringen gecoördineerd op 14 juli 1994, met het oog op een financieel toegankelijker geneesmiddelenbeleid binnen de ziekenhuizen/Proposition de loi modifiant la loi relative à l’assurance obligatoire soins de santé et indemnités coordonnée le 14 juillet 1994, afin que les hôpitaux mènent une politique des médicaments qui les rende financièrement plus abordables - the Bill, see attachment). The Bill became publicly available just a few weeks ago.
 
Ms. Farih expects a larger uptake of biosimilars in hospitals to make biological medicines more accessible for patients and, more plausibly, to create additional savings on the health budget. The Bill is predicated on the finding that the biosimilar uptake in Belgian hospitals is still low and that this is attributable to a deficient application of the public procurement rules which most hospitals in Belgium are supposed to abide by.
 
On that basis, the Bill proposes to: 

  • Oblige hospitals to have the biological reference product and the biosimilar product form part of the same subdivision (perceel/lot) in any given request for proposals.
  • Oblige hospitals to issue a call for tenders within 90 calendar days following the entry into force of reimbursement conditions for a new biosimilar. This obligation will come into play even if the hospital at issue has a pending contractual obligation to procure the reference biological product or another competing biosimilar medicine.
  • Oblige hospitals to start a new procurement regime within 60 calendar days following the receipt of offers in response to a request for proposals.
  • Limit the duration of any new supply agreement to 24 months, with the possible option, subject to conditions, to extend the agreement for a further 12 months.
  • Guarantee the equal treatment of the reference biological products and the biosimilars. A model request for proposals may be established by Royal Decree.
  • Create rules that will exempt hospitals from the application of the new procurement rules for biological products as soon as the biosimilars obtain a specific share of the market for a given active substance.

The Bill was prompted by a study published by the Christian sick-fund, one of Belgium’s major healthcare payors. While the Bill is a private member’s initiative, it may still gain traction, either autonomously or as part of a wider governmental initiative to promote biosimilars, which is one of the policy objectives of the current federal government.    

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 19/07/2022
    • Articles

    European Commission Continues to Pursue "Gun Jumping" Merger Control Proceedings against Illumina and Grail

    On 20 August 2021, the European Commission (the Commission) said that it would investigate whether Illumina’s decision, made public on 18 August 2021, to acquire Grail pending the Commission’s review of that transaction under Regulation 139/2004 on the control of concentrations between undertakings (the Merger Regulation) is in breach of the “standstill obligation” provided for by Article 7, Merger Regulation. Pursuant to this provision, a concentration notifiable under the Merger Regulation must not be implemented until after the Commission has approved it (see, Van Bael & Bellis Life Sciences News and Insights of 24 August 2021).

    Read more
    • 15/07/2022
    • News

    European Commission Publishes Proposal for Regulation on Substances of Human Origin

    On 14 July 2022, the European Commission (the Commission) published its long-awaited Proposal for a Regulation on standards of quality and safety for substances of human origin intended for human application (COM(2022) 338 final; the proposed Regulation) and an accompanying Q&A document (see, attachments). The proposed Regulation updates the current regulatory framework to improve safety and quality standards applicable to substances of human origin (so-called SoHOs). SoHOs include blood, tissues, cells and any other substances of human origin like human breast milk and microbiota. SoHOs can be directly intended for human application but can also be used in preparations or in manufactured products. Article 2 of the proposed Regulation provides for a list of “SoHO activities” that fall within the scope of the proposed Regulation. The list includes activities such as donor recruitment, processing of SoHOs, distribution, import and export of SoHOs and human application of SoHOs.   The proposed Regulation will apply to all SoHOs. Only solid organs used for transplantation will remain regulated separately under the Organs Directive (Directive 2010/45/EU). In view of the broad definition of the term SoHOs, the proposed Regulation will be future-proof in the sense that it will automatically apply to new substances of human origin that can be applied to patients. A key aspect of the proposed Regulation is that it empowers the Commission to adopt implementing acts regarding patient, donor and offspring protection. However, in the absence of such implementing acts, “SoHO entities” (which are defined in Article 3(24) as “organisation[s] legally established in the Union that carr[y] out one or more of the SoHO activities”) will have to apply standards established by the European Centre for Disease Prevention and Control and the European Directorate for the Quality of Medicines & HealthCare of the Council of Europe. The aim is to ensure that technical rules applicable to SoHO activities remain updated and to avert the accumulation of obsolete rules which would stand in the way of novel SoHO-based treatments and new medical techniques. For purposes of enforcement, the Commission devised a supervision mechanism based on national Competent Authorities. Chapters II and III of the proposed Regulation are dedicated to, respectively, “Competent Authorities” and “SoHO Supervisory Activities”. The rules enable extensive coordination between the different national Competent Authorities and the Commission. According to the Commission, increased harmonisation in the field of SoHO activities between EU countries could bring significant improvements in treatments such as stem, cornea, or skin transplants. Facilitated exchanges of SoHOs could even save lives, especially for conditions like blood cancer for which blood supply is of critical importance. The proposed Regulation will now be discussed by the Council and the European Parliament. Once the final text is agreed, adopted and published, most of the provisions will take effect after a transition period of two years.

    Read more
    • 14/07/2022
    • Articles

    General Court Confirms European Commission's Power to Review Illumina-Grail Even Though EU and National Turnover Thresholds Are Not Reached

    Yesterday, the General Court of the European Union came down on the side of the European Commission (the Commission) in that agency’s dispute with genomics firm Illumina and held that the Commission has jurisdiction to examine Illumina's acquisition of cancer detection test start-up Grail, even though the transaction escapes the European and Member State turnover thresholds for review (case T-227/21, Illumina, Inc. v. European Commission – see, attachment).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *